Zhoufeng Wang

2.6k total citations · 1 hit paper
71 papers, 1.6k citations indexed

About

Zhoufeng Wang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Zhoufeng Wang has authored 71 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Zhoufeng Wang's work include Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (7 papers) and Cancer-related molecular mechanisms research (6 papers). Zhoufeng Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (7 papers) and Cancer-related molecular mechanisms research (6 papers). Zhoufeng Wang collaborates with scholars based in China, United States and Botswana. Zhoufeng Wang's co-authors include Yanfen Wang, Benxia Li, Tongxuan Liu, Weimin Li, Fang Liao, Chengdi Wang, Kang Zhang, Guangyu Wang, Johnson Yiu‐Nam Lau and Siwei Yang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Zhoufeng Wang

65 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COVID-19 in early 2021: current status and looking forward

2021 197 citations Chengdi Wang, Zhoufeng Wang et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhoufeng Wang China	19	417	354	292	266	256	71	1.6k
Xueli Wang China	28	562 1.3×	725 2.0×	270 0.9×	156 0.6×	161 0.6×	154	2.5k
Lili Du China	31	417 1.0×	819 2.3×	385 1.3×	154 0.6×	228 0.9×	69	2.5k
Zhen Zhou China	23	243 0.6×	482 1.4×	193 0.7×	209 0.8×	267 1.0×	172	2.2k
Dahee Kim South Korea	22	295 0.7×	225 0.6×	645 2.2×	189 0.7×	214 0.8×	135	2.1k
Yuanyuan Hao China	20	316 0.8×	311 0.9×	287 1.0×	219 0.8×	168 0.7×	102	1.7k
Anna Maria Ferretti Italy	27	598 1.4×	420 1.2×	296 1.0×	299 1.1×	59 0.2×	93	2.1k
Qiubo Zhang China	25	724 1.7×	345 1.0×	363 1.2×	68 0.3×	263 1.0×	86	2.1k
Xiaoyu Dong China	20	281 0.7×	227 0.6×	250 0.9×	284 1.1×	134 0.5×	86	1.4k
Yunjie Zhang China	19	257 0.6×	351 1.0×	150 0.5×	126 0.5×	99 0.4×	113	1.6k
Lixia Ma China	21	438 1.1×	928 2.6×	419 1.4×	136 0.5×	289 1.1×	57	2.3k

Countries citing papers authored by Zhoufeng Wang

Since Specialization

Citations

This map shows the geographic impact of Zhoufeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhoufeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhoufeng Wang more than expected).

Fields of papers citing papers by Zhoufeng Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhoufeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhoufeng Wang. The network helps show where Zhoufeng Wang may publish in the future.

Co-authorship network of co-authors of Zhoufeng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhoufeng Wang. A scholar is included among the top collaborators of Zhoufeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhoufeng Wang. Zhoufeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Zhoufeng, et al.. (2025). Study on the kinetics and mechanism of thermal decomposition of bisphenol A-type polyarylates. Journal of Analytical and Applied Pyrolysis. 188. 107040–107040. 1 indexed citations

Chen, Weilong, Jinian Yang, Jie Liu, et al.. (2025). Significance of structurally inherited nickel/cobalt bimetallic phyllosilicates for enhancing the mechanical, thermal and dry-sliding properties of epoxy composites. Construction and Building Materials. 472. 140898–140898. 5 indexed citations

Wang, Zhoufeng, Shuo Liu, Chang Chen, et al.. (2025). Empagliflozin ameliorates RSL3-induced ferroptosis in vascular endothelial cells via the NRF2/HO-1 pathway. BMC Cardiovascular Disorders. 25(1). 437–437. 2 indexed citations

Wang, Chengdi, Jingwei Li, Jingyao Chen, et al.. (2025). Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer. Nature Communications. 16(1). 1477–1477. 13 indexed citations

Li, Yuepeng, Xiaolong Tang, Rui Zhang, et al.. (2025). Research progress in early states of chronic obstructive pulmonary disease: a narrative review on PRISm, pre-COPD, young COPD and mild COPD. Expert Review of Respiratory Medicine. 19(10). 1063–1079. 1 indexed citations

Zhou, Chengzhi, Junru Chen, Xingxiang Xu, et al.. (2025). 12P: Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial. Journal of Thoracic Oncology. 20(3). S16–S17.

Wang, Kai, Jun Xiang, Zhoufeng Wang, et al.. (2025). Development and validation of a transcription factor regulatory network‐based signature for individualized prognostic risk in lung adenocarcinoma. International Journal of Cancer. 156(12). 2440–2451.

Wang, Wenke, et al.. (2025). Evolution of geochemical processes driven by hydrogeological processes in the hierarchically nested groundwater flow system in the Ordos Basin, China. Journal of Environmental Management. 392. 126709–126709. 1 indexed citations

Wang, Xin, et al.. (2025). Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis. MedComm. 6(3). e70080–e70080. 3 indexed citations

10.

Wang, Zhoufeng, et al.. (2025). Kinetic and mechanism analysis of thermal decomposition of hexafluorobisphenol A-containing polyarylates. Journal of Analytical and Applied Pyrolysis. 194. 107512–107512.

11.

Rao, Guanhua, Guonian Zhu, Lijuan Yuan, et al.. (2023). Dysbiosis of lower respiratory tract microbiome are associated with proinflammatory states in non‐small cell lung cancer patients. Thoracic Cancer. 15(2). 111–121. 4 indexed citations

12.

Zhang, Fengmei, et al.. (2023). Dual-Target Inhibitors Based on COX-2: A Review from Medicinal Chemistry Perspectives. Future Medicinal Chemistry. 15(23). 2209–2233. 3 indexed citations

13.

Zhang, Qin, et al.. (2023). Team-based learning vs. lecture-based learning in nursing: A systematic review of randomized controlled trials. Frontiers in Public Health. 10. 1044014–1044014. 14 indexed citations

14.

Cui, Zhen, Wenxin Luo, Ruihong Chen, et al.. (2023). Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds. Signal Transduction and Targeted Therapy. 8(1). 179–179. 8 indexed citations

15.

Xu, Hanyue, Hao Zhang, Wen Guo, et al.. (2022). Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. BMC Cancer. 22(1). 923–923. 8 indexed citations

16.

Deng, Hui, Qian Lei, Chengdi Wang, et al.. (2022). A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. Nature Communications. 13(1). 6944–6944. 27 indexed citations

17.

Wang, Chengdi, Zhoufeng Wang, Guangyu Wang, et al.. (2021). COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy. 6(1). 114–114. 197 indexed citations breakdown →

18.

Yang, Jianhong, Yamei Yu, Yong Li, et al.. (2021). Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect. Science Advances. 7(21). 48 indexed citations

19.

Wang, Zhoufeng, Zhe Li, Kun Zhou, et al.. (2021). Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nature Communications. 12(1). 6500–6500. 98 indexed citations

20.

Wang, Zhoufeng, et al.. (2018). Recent Advances of Molecular Genetic Characteristics of Lung Cancer. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact